Catalyst Pharmaceuticals (CPRX) Operating Margin (2018 - 2026)
Catalyst Pharmaceuticals posted quarterly Operating Margin of 49.02% for Q1 2026, up 421.0% year-on-year from 9.41% in Q1 2025, and up 20.96% on a QoQ basis from 40.52% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 9 years of Operating Margin data on file, last reported at 49.02% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 421.0% year-over-year to 49.02%; the trailing twelve-month figure through Mar 2026 stood at 44.83% (up 156.0% YoY), and the FY2025 full-year result was 43.77%, up 409.0% from the prior year.
- Operating Margin for Q1 2026 stood at 49.02%, up from 40.52% in the prior quarter.
- Across five years, Operating Margin topped out at 53.79% in Q2 2022 and bottomed at 36.21% in Q3 2023.
- The 5-year median for Operating Margin is 44.21% (2024), against an average of 38.74%.
- The widest annual swing landed in 2023, when Operating Margin tumbled 8007 bps; it then surged 7577 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 50.7% in 2022, then declined by 26 bps to 37.71% in 2023, then gained by 18 bps to 44.31% in 2024, then retreated by 9 bps to 40.52% in 2025, then advanced by 21 bps to 49.02% in 2026.
- The last three Operating Margin figures came in at 49.02% (Q1 2026), 40.52% (Q4 2025), and 44.66% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 49.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.02% |
| Dec 31, 2025 | 40.52% |
| Sep 30, 2025 | 44.66% |
| Jun 30, 2025 | 45.24% |
| Mar 31, 2025 | 44.81% |
| Dec 31, 2024 | 44.31% |
| Sep 30, 2024 | 39.56% |
| Jun 30, 2024 | 44.21% |
| Mar 31, 2024 | 27.54% |
| Dec 31, 2023 | 37.71% |
| Sep 30, 2023 | -36.21% |
| Jun 30, 2023 | 46.90% |
| Mar 31, 2023 | 41.71% |
| Dec 31, 2022 | 50.70% |
| Sep 30, 2022 | 43.85% |
| Jun 30, 2022 | 53.79% |
| Mar 31, 2022 | 40.30% |
| Dec 31, 2021 | 33.26% |
| Sep 30, 2021 | 38.95% |
| Jun 30, 2021 | 43.55% |
| Mar 31, 2021 | 32.45% |
| Dec 31, 2020 | 27.79% |
| Sep 30, 2020 | 39.92% |
| Jun 30, 2020 | 34.73% |
| Mar 31, 2020 | 36.72% |
| Dec 31, 2019 | 26.58% |
| Sep 30, 2019 | 44.81% |
| Jun 30, 2019 | 38.00% |
| Mar 31, 2019 | -7.93% |
| Dec 31, 2018 | -2,968.65% |